HC Wainwright Has Negative Forecast for Celcuity Q1 Earnings

Key Points

• HC Wainwright slightly lowered its Q1 2026 EPS estimate for Celcuity to ($1.05) from ($1.04) and projects the company will turn profitable in later years (FY2027 $1.77, FY2028 $7.60, FY2029 $12.01, FY2030 $16.69).
• Topline Phase 3 VIKTORIA‑1 results reportedly showed gedatolisib improved progression‑free survival versus Novartis’ alpelisib, prompting planned regulatory/ASCO catalysts and multiple analyst upgrades that have lifted the stock.
• Despite strong analyst price targets and a consensus "Moderate Buy" ($134.50), Celcuity carries high valuation, negative current EPS and recent insider selling, leaving material volatility and downside risk if upcoming data or regulatory steps disappoint.

Celcuity, Inc. (NASDAQ:CELC - Free Report) - Equities researchers at HC Wainwright dropped their Q1 2026 earnings per share estimates for shares of Celcuity in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($1.05) per share for the quarter, down from their prior estimate of ($1.04). The consensus estimate for Celcuity's current full-year earnings is ($3.97) per share. HC Wainwright also issued estimates for Celcuity's Q2 2026 earnings at ($1.12) EPS, Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at $1.77 EPS, FY2028 earnings at $7.60 EPS, FY2029 earnings at $12.01 EPS and FY2030 earnings at $16.69 EPS.

CELC has been the subject of several other research reports. Wolfe Research reiterated an "outperform" rating and issued a $110.00 target price on shares of Celcuity in a research note on Thursday, March 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Celcuity in a research report on Monday, April 20th. Citigroup restated an "outperform" rating on shares of Celcuity in a report on Monday. Guggenheim upped their price objective on shares of Celcuity from $135.00 to $165.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a research note on Monday. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $134.50.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $141.69 on Wednesday. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The stock's fifty day simple moving average is $115.27 and its two-hundred day simple moving average is $103.28. Celcuity has a 1-year low of $9.51 and a 1-year high of $151.02. The stock has a market cap of $6.85 billion, a PE ratio of -37.39 and a beta of 0.09.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.09.

Insider Transactions at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the firm's stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the sale, the director directly owned 6,760 shares of the company's stock, valued at $745,425.20. This trade represents a 30.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently made changes to their positions in CELC. Avoro Capital Advisors LLC purchased a new stake in Celcuity during the fourth quarter worth about $310,302,000. NEA Management Company LLC raised its position in Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company's stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the period. State Street Corp boosted its stake in Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company's stock valued at $163,343,000 after acquiring an additional 914,887 shares during the last quarter. Apis Capital Advisors LLC bought a new position in shares of Celcuity during the 3rd quarter valued at approximately $38,334,000. Finally, UBS Group AG grew its position in shares of Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company's stock valued at $42,211,000 after acquiring an additional 769,891 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Topline Phase 3 VIKTORIA‑1 results reportedly show gedatolisib improved progression‑free survival vs Novartis’ alpelisib in the PIK3CA‑mutant cohort — a direct efficacy win versus a marketed competitor that materially strengthens commercial prospects. Celcuity’s gedatolisib beats Novartis drug in Phase III test
• Positive Sentiment: Company says it will pursue a supplemental NDA filing for the PIK3CA‑mutant data and will present detailed results at ASCO — this creates a clear near‑term regulatory/visibility catalyst on top of the already accepted NDA for a different subgroup. Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib
• Positive Sentiment: Multiple analysts raised ratings/targets after the news (Needham to $157, Citizens/JMP to $160 and others), which likely amplified buying and gave investors new valuation anchors. Needham & Company LLC Issues Positive Forecast for Celcuity NASDAQ: CELC Stock Price
• Neutral Sentiment: Broad media coverage (MarketWatch, FierceBiotech, Yahoo/Finance) is increasing awareness ahead of ASCO and the upcoming PDUFA for the previously accepted NDA, pushing volumes and short‑term attention. Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results
• Neutral Sentiment: Clinical summaries and independent coverage recap VIKTORIA‑1 toplines and planned ASCO presentation; these reports inform but leave detailed subgroup and safety readouts pending (ASCO presentation will be important). Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
• Negative Sentiment: Insider selling has been reported recently (multiple open‑market sales), which some investors view as a cautionary signal despite positive trial news. Insider trading and institutional flow summary
• Negative Sentiment: High valuation and negative reported EPS mean the stock’s rally rests on future commercial execution and regulatory approvals; volatility and downside risk remain if upcoming ASCO or FDA updates disappoint. Valuation note

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.